Όλο το DSpace

Πλοήγηση ανά Θέμα "prednisone"

Αποτελέσματα 1-20 από 21

    • Anti-angiogenic effect of a Palladium(II)-Saccharinate Complex of Terpyridine in vitro and in vivo 

      Ikitimur-Armutak E.I., Gurel-Gurevin E., Kiyan H.T., Aydinlik S., Yilmaz V.T., Dimas K., Ulukaya E. (2017)
      Anti-angiogenic activity of palladium (Pd)(II)-based complexes is unknown despite their quite powerful anticancer activity. This study was therefore carried out to evaluate both in vivo anti-angiogenic effect and in vitro ...

    • Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer 

      Pagkopoulou E., Simopoulou T., Maragkouli E., Perifanou-Sotiri S., Kotsakis A., Bogdanos D.P. (2020)
      Immune checkpoint inhibitors (ICIs) are a new class of drug that have demonstrated efficacy across many cancer types. Because of their nature and mode of action, ICIs unleash immune activation raising concerns as to whether ...

    • Chloroquine used in combination with chemotherapy synergistically suppresses growth and angiogenesis in vitro and in vivo 

      Gurel-Gurevin E., Tuba Kiyan H., Esener O.B.B., Aydinlik S., Uvez A., Ulukaya E., Dimas K., Armutak E.I. (2018)
      Background: The inhibition of autophagy using pharmacological inhibitors such as chloroquine may be an effective strategy to overcome chemotherapy or resistance to anti-angiogenic therapy. Materials and Methods: The cytotoxic ...

    • Clinical and financial burden of active lupus in Greece: A nationwide study 

      Bertsias G., Karampli E., Sidiropoulos P., Gergianaki I., Drosos A., Sakkas L., Garyfallos A., Tzioufas A., Vassilopoulos D., Tsalapaki C., Sfikakis P., Panopoulos S., Athanasakis K., Perna A., Psomali D., Kyriopoulos J., Boumpas D.T. (2016)
      Analyses of the medical and economic burden of chronic disorders such as systemic lupus erythematosus (SLE) are valuable for clinical and health policy decisions. We performed a chart-based review of 215 adult SLE patients ...

    • Current guidelines for the management of idiopathic pulmonary fibrosis 

      Antoniou, K. M.; Daniil, Z.; Polychronopoulos, V.; Papiris, S.; Bouros, D. (2012)

    • How can we effectively address the paraneoplastic dermatomyositis: Diagnosis, risk factors and treatment options 

      Zerdes I., Tolia M., Nikolaou M., Tsoukalas N., Velentza L., Hajiioannou J., Mitsis M., Kyrgias G. (2017)
      Purpose: Dermatomyositis (DM) represents an auto-immune inflammatory myopathy. In this review, we analyzed the incidence of DM as a clinical manifestation highlighting the peculiar clinical and treatment characteristics ...

    • Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP 

      Vassilakopoulos T.P., Michail M., Papageorgiou S., Kourti G., Angelopoulou M.K., Panitsas F., Sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Terpos E., Dimopoulou M.N., Karakatsanis S., Michalis E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Economopoulos T., Kyriazopoulou L., Siakantaris M.P., Kyrtsonis M.-C., Symeonidis A., Anargyrou K., Papaioannou M., Hatjiharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Gainaru G., Stefanoudaki E., Zikos P., Tsirigotis P., Tsourouflis G., Assimakopoulou T., Konstantinidou P., A. Papadaki H., Megalakaki K., Dimopoulos M.-A., Pappa V., Karmiris T., Roussou P., Panayiotidis P., Konstantopoulos K., Pangalis G.A. (2021)
      Background: R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective ...

    • IL-10-producing regulatory B cells (B10 cells), IL-17 + T cells and autoantibodies in systemic sclerosis 

      Mavropoulos A., Liaskos C., Simopoulou T., Bogdanos D.P., Sakkas L.I. (2017)
      We aimed to analyze IL-10 + Breg (B10) cells, found to be reduced in systemic sclerosis (SSc), in relation to SSc-specific autoAbs and IL-17 + and IFNγ + T cells in SSc. Peripheral blood B10 cells from 26 patients with SSc ...

    • Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies 

      Vassilakopoulos T.P., Papageorgiou S.G., Angelopoulou M.K., Chatziioannou S., Prassopoulos V., Karakatsanis S., Arapaki M., Mellios Z., Sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Terpos E., Michali E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Siakantaris M.P., Kyrtsonis M.-C., Symeonidis A., Anargyrou K., Papaioannou M., Chatziharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Gainaru G., Mainta C., Tsirigotis P., Assimakopoulou T., Konstantinidou P., Papadaki H., Dimopoulos M.-A., Pappa V., Karmiris T., Roussou P., Datseris I., Panayiotidis P., Konstantopoulos K., Pangalis G.A., Rondogianni P. (2021)
      End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the ...

    • Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry 

      Giannis D., Allen S.L., Tsang J., Flint S., Pinhasov T., Williams S., Tan G., Thakur R., Leung C., Snyder M., Bhatia C., Garrett D., Cotte C., Isaacs S., Gugerty E., Davidson A., Marder G.S., Schnitzer A., Goldberg B., McGinn T., Davidson K.W., Barish M.A., Qiu M., Zhang M., Goldin M., Matsagkas M., Arnaoutoglou E., Spyropoulos A.C. (2021)
      Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in coronavirus disease 2019 (COVID-19) inpatients. Whether ...

    • Primary extranodal non Hodgkin's lymphoma of the head and neck in adults: A clinicopathological comparison between tonsillar and non tonsillar lymphomas 

      Economopoulos, T.; Fountzilas, G.; Kostourou, A.; Daniilidis, J.; Pavlidis, N.; Andreopoulou, H.; Nicolaou, A.; Papageorgiou, E.; Mellou, S.; Dervenoulas, J.; Stathakis, N. (1998)
      Primary extranodal NHL of the head and neck (HN-NHL) accounts for 10-20% of all cases of NHL. Despite their frequency, the natural history and biological behaviour of these lymphomas is poorly understood. In this study we ...

    • Primary retroperitoneal non-Hodgkin lymphoma presenting with torturous generalized pruritus in an elderly 

      Daponte, A.; Ioannou, M.; Gioti, C.; Kallitsaris, A.; Dalekos, G. N.; Messinis, I. E. (2007)
      Introduction: A case of a rare primary retroperitoneal non-Hodgkin lymphoma (NHL), which presented with torturous generalized pruritus in a 74-year-old female patient is reported Methods: Case report. Results: Explorative ...

    • A proposed medication score for long-term trials of treatment of canine atopic dermatitis sensu lato 

      Saridomichelakis M.N., Favrot C., Jackson H.A., Bensignor E., Prost C., Mueller R.S. (2021)
      Background: The use of concurrent medications is necessary in trials of treatment of canine atopic dermatitis. Our aim was to use the best available evidence to construct and then to validate a medication score (MS) formula ...

    • Prostate cancer: ESMO consensus conference guidelines 2012 

      Horwich, A.; Hugosson, J.; de reijke, T.; Wiegel, T.; Fizazi, K.; Kataja, V.; Parker, C.; Bellmunt, J.; Berthold, D.; Bill-axelson, A.; Carlsson, S.; Daugaard, G.; De meerleer, G.; De reijke, T.; Dearnaley, D.; Fonteyne, V.; Gillessen, S.; Heinrich, D.; Kwiatkowski, M.; Nilsson, S.; Padhani, A.; Papandreou, C.; Roobol, M.; Sella, A.; Valdagni, R.; Van der kwast, T.; Verhagen, P. (2013)
      The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological ...

    • Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma 

      Karakatsanis S.J., Bouzani M., Symeonidis A., Angelopoulou M.K., Papageorgiou S.G., Michail M., Gainaru G., Kourti G., sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Kanellias N., Dimopoulou M.N., Michali E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Economopoulos T., Kyriazopoulou L., Siakantaris M.P., Kyrtsonis M.-C., Anargyrou K., Papaioannou M., Hatjiharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Stefanoudaki E., Zikos P., Tsirigotis P., Tsourouflis G., Assimakopoulou T., Verrou E., Papadaki H., Lampropoulou P., Dimopoulos M.-A., Pappa V., Konstantopoulos K., Karmiris T., Roussou P., Panayiotidis P., Pangalis G.A., Vassilakopoulos T.P. (2022)
      Background/Aim: Primary mediastinal large Bcell lymphoma (PMLBCL) is an aggressive B-cell non- Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody ...

    • Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: A multicenter national study by the Greek Myeloma Study Group 

      Katodritou E., Terpos E., Delimpasi S., Kotsopoulou M., Michalis E., Vadikolia C., Kyrtsonis M.-C., Symeonidis A., Giannakoulas N., Vadikolia C., Michael M., Kalpadakis C., Gougopoulou T., Prokopiou C., Kaiafa G., Christoulas D., Gavriatopoulou M., Giannopoulou E., Labropoulou V., Verrou E., Kastritis E., Konstantinidou P., Anagnostopoulos A., Dimopoulos M.A. (2018)
      We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated upfront with novel agent-based ...

    • Sickle cell trait-related ischemic colitis in a patient with Sjögren's syndrome 

      Manolakis, A. C.; Kapsoritakis, A. N.; Ioannou, M.; Tsikouras, A. N.; Koukoulis, G. K.; Potamianos, S. P. (2008)

    • Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement 

      Lesche D., Sigurdardottir V., Leichtle A.B., Nakas C.T., Christians U., Englberger L., Fiedler M., Largiadèr C.R., Mohacsi P., Sistonen J. (2018)
      Introduction: The immunosuppressive therapy with everolimus (ERL) after heart transplantation is characterized by a narrow therapeutic window and a substantial variability in dose requirement. Factors explaining this ...

    • Tuberculous pyomyositis: A re-emerging entity of many faces 

      Simopoulou T., Varna A., Dailiana Z., Katsiari C., Alexiou I., Basdekis G., Malizos K.N., Sakkas L.I. (2016)
      Tuberculosis (TB) has become a global concern due to its increasing incidence, particularly in immunocompromised patients, closely following the migratory patterns of populations. TB pyomyositis is a rare extrapulmonary ...

    • Type 1 autoimmune hepatitis presenting with severe autoimmune neutropenia 

      Doumtsis P., Oikonomou T., Goulis I., Zachou K., Dalekos G., Cholongitas E. (2018)
      Autoimmune hepatitis (AIH) is a progressive, chronic liver disease characterized by unresolving hepatocellular inflammation of autoimmune origin. The clinical spectrum may vary from asymptomatic presentation, to non-specific ...